Cytokinetics Inc. (CYTK) — Analysis Summary
Cytokinetics Inc. (CYTK) has a market cap of $10.42B with year-over-year revenue growth of +376.6%. Net margin stands at -891.6%. The stock trades at a P/E ratio of -12.6.
Key Takeaways
- Revenue changed +376.6% year-over-year
- Net margin of -891.6%
- P/E ratio of -12.6
Compared to other companies in the PHARMACEUTICAL PREPARATIONS sector, CYTK posted revenue growth of +376.6% and trades at a P/E of -12.6.
Disclaimer: This is not financial advice. Data sourced from SEC EDGAR and Polygon.io. Past performance does not guarantee future results. Always conduct your own research before making investment decisions.